 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...121122123124125126127128129130131132133» |
- ||||| New P4 trial: Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors (clinicaltrials.gov) - Jul 26, 2012
P4, N=100, Recruiting, Sponsor: Hospital do Rim e Hipertensão
- everolimus / Generic mfg.
Enrollment open, Metastases: Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors (clinicaltrials.gov) - Jul 24, 2012
P2, N=29, Recruiting, Sponsor: Hellenic Cooperative Oncology Group
Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
Biomarker, Enrollment change: Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity (clinicaltrials.gov) - Jul 23, 2012
P2, N=9, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting N=39 --> 9
- everolimus / Generic mfg.
Biomarker, Trial completion: Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity (clinicaltrials.gov) - Jul 23, 2012
P2, N=9, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=39 --> 9 Active, not recruiting --> Completed
- | everolimus / Generic mfg.
Enrollment change, Metastases: Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium (clinicaltrials.gov) - Jul 22, 2012
P2, N=46, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed N=37 --> 46
- everolimus / Generic mfg.
New P2 trial, Metastases: Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors (clinicaltrials.gov) - Jul 22, 2012
P2, N=29, Recruiting, Sponsor: Hellenic Cooperative Oncology Group
- letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Enrollment change: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Jul 18, 2012
P2, N=84, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=37 --> 46 N=28 --> 84
- | letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
New P2 trial: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Jul 15, 2012
P2, N=84, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- everolimus / Generic mfg.
Biomarker, New P1 trial: Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer (clinicaltrials.gov) - Jul 15, 2012
P1, N=0, Withdrawn, Sponsor: University of Michigan Cancer Center
- everolimus / Generic mfg.
Clinical: EVERTWIST: Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation (clinicaltrials.gov) - Jul 12, 2012
P=N/A, N=58, Recruiting, Sponsor: IRCCS Policlinico S. Matteo
- |||| Trial completion: SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus (clinicaltrials.gov) - Jul 11, 2012
P4, N=126, Completed, Sponsor: Novartis Pharmaceuticals
N=28 --> 84 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Enrollment closed: GeparQuinto: Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (clinicaltrials.gov) - Jul 10, 2012
P3, N=2600, Active, not recruiting, Sponsor: German Breast Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P1 trial, Metastases: Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer (clinicaltrials.gov) - Jul 9, 2012
P1, N=12, Completed, Sponsor: Fox Chase Cancer Center
- | everolimus / Generic mfg.
Enrollment change: Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) (clinicaltrials.gov) - Jul 8, 2012
P1/2, N=20, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Active, not recruiting N=10 --> 20
- |||||||||| New P3 trial: The Everolimus-Transplant Exit Strategy Trial (E-TEST) (clinicaltrials.gov) - Jul 8, 2012
P3, N=60, Recruiting, Sponsor: Allan D Kirk, MD, PhD
- Votrient (pazopanib) / Novartis, sunitinib / Generic mfg., Zelboraf (vemurafenib) / Roche
Metastases: ICK: Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. (clinicaltrials.gov) - Jul 8, 2012
P=N/A, N=40, Recruiting, Sponsor: VU University Medical Center
- | everolimus / Generic mfg.
New P2 trial: Everolimus in Treating Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Jul 8, 2012
P2, N=39, Recruiting, Sponsor: Boston Medical Center
- ||||| Herceptin (trastuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: BOLERO-3: Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jul 8, 2012
P3, N=570, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=10 --> 20 Recruiting --> Active, not recruiting
- ||| temozolomide / Generic mfg., everolimus / Generic mfg.
Enrollment closed: Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Jul 7, 2012
P1/2, N=138, Active, not recruiting, Sponsor: North Central Cancer Treatment Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
Enrollment change: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Jul 2, 2012
P2, N=33, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting N=60 --> 33
- everolimus / Generic mfg.
Trial termination, Combination therapy: Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC (clinicaltrials.gov) - Jul 1, 2012
P1, N=3, Terminated, Sponsor: University of Chicago
N=60 --> 33 Recruiting --> Terminated; Poor accrual
- everolimus / Generic mfg.
Enrollment change, Combination therapy: Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC (clinicaltrials.gov) - Jul 1, 2012
P1, N=3, Terminated, Sponsor: University of Chicago
Recruiting --> Terminated; Poor accrual N=24 --> 3
- | prednisone / Generic mfg., everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
New P4 trial, IO biomarker: Renal Transplantation in the Elderly - nEverOld Study (clinicaltrials.gov) - Jun 26, 2012
P4, N=90, Recruiting, Sponsor: University of Sao Paulo General Hospital
- ||||| dactolisib (RTB101) / Adicet Bio
New P2 trial, Metastases: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Jun 25, 2012
P2, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
- | everolimus / Generic mfg.
Enrollment open: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) (clinicaltrials.gov) - Jun 24, 2012
P4, N=20, Recruiting, Sponsor: Novartis Pharmaceuticals
N=24 --> 3 Not yet recruiting --> Recruiting
- metformin / Generic mfg., everolimus / Generic mfg., exemestane / Generic mfg.
New P2 trial, Metastases: Exemestane-RAD001-Metformin (clinicaltrials.gov) - Jun 21, 2012
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
- |||||||||| everolimus / Generic mfg., exemestane / Generic mfg.
New P3 trial, HEOR, Combination therapy, Metastases: MACS2096: 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 20, 2012
P3, N=302, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- | New P4 trial: Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients (clinicaltrials.gov) - Jun 19, 2012
P4, N=60, Enrolling by invitation, Sponsor: University of California, San Francisco
- |||||||||| Simulect (basiliximab) / Novartis
New P3 trial: SIMCER: A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients (clinicaltrials.gov) - Jun 19, 2012
P3, N=184, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Prolia (denosumab) / Amgen, Daiichi Sankyo, Kineret (anakinra) / SOBI
New P1 trial, Combination therapy, Metastases: NCI-2018-01842: Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers (clinicaltrials.gov) - Jun 19, 2012
P1, N=147, Recruiting, Sponsor: M.D. Anderson Cancer Center
- everolimus / Generic mfg., erlotinib / Generic mfg.
Trial termination, Metastases: Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer (clinicaltrials.gov) - Jun 17, 2012
P2, N=16, Terminated, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Completed --> Terminated; Significant Adverse Effects - Futility
- |||| everolimus / Generic mfg., vinorelbine tartrate / Generic mfg.
Enrollment open, Combination therapy, Monotherapy, Metastases: VicTORia: Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer (clinicaltrials.gov) - Jun 12, 2012
P2, N=166, Recruiting, Sponsor: AIO-Studien-gGmbH
Completed --> Terminated; Significant Adverse Effects - Futility Not yet recruiting --> Recruiting
- patupilone (EPO 906) / Novartis
Trial completion: Phase I Study of Patupilone and RAD001 (clinicaltrials.gov) - Jun 12, 2012
P1, N=42, Completed, Sponsor: University of Medicine and Dentistry New Jersey
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| lapatinib / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Trial initiation date, Combination therapy, Metastases: Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer (clinicaltrials.gov) - Jun 11, 2012
P2, N=76, Recruiting, Sponsor: University of Maryland
Active, not recruiting --> Completed Initiation date: Jan 2012 --> May 2012
- |||| lapatinib / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment open, Combination therapy, Metastases: Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer (clinicaltrials.gov) - Jun 11, 2012
P2, N=76, Recruiting, Sponsor: University of Maryland
Initiation date: Jan 2012 --> May 2012 Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
Trial completion, IO biomarker: SAKK 36/06: Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov) - Jun 7, 2012
P2, N=35, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Sutent (sunitinib) / Pfizer
New P2 trial, Metastases: Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Jun 7, 2012
P2, N=0, Withdrawn, Sponsor: Andrea Harzstark
- everolimus / Generic mfg.
Enrollment closed, Surgery: S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 5, 2012
P2, N=55, Active, not recruiting, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Clinical: Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients (clinicaltrials.gov) - Jun 3, 2012
P=N/A, N=60, Recruiting, Sponsor: University of Kentucky
- Enrollment change: Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome (clinicaltrials.gov) - Jun 3, 2012
P2, N=3, Terminated, Sponsor: University of Utah
Recruiting --> Active, not recruiting N=10 --> 3
- | everolimus / Generic mfg.
Trial initiation date: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) (clinicaltrials.gov) - May 29, 2012
P4, N=20, Recruiting, Sponsor: Novartis Pharmaceuticals
N=10 --> 3 Initiation date: Dec 2011 --> May 2012
- | everolimus / Generic mfg.
New P4 trial: A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus (clinicaltrials.gov) - May 29, 2012
P4, N=120, Recruiting, Sponsor: Hospital de Clinicas de Porto Alegre
- ||||| Sutent (sunitinib) / Pfizer
New P2 trial, Metastases: A randomized study to explore the efficacy and feasibility of rotations between sunitinib and everolimus versus sequential treatment of sunitinib and everolimus until progression in patients with renal cancer. Estudio aleatorizado, para explorar la eficacia y la viabilidad de rotaciones entre sunitinib y everolimus, en comparaci (EUDRACT) - May 28, 2012
P2, N=115, Ongoing, Sponsor: APRO
- Signifor (pasireotide) / Recordati
New P2 trial, Combination therapy: SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer (clinicaltrials.gov) - May 24, 2012
P2, N=19, Recruiting, Sponsor: Federico II University
- everolimus / Generic mfg., capecitabine / Generic mfg.
Trial termination, Combination therapy, Metastases: Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast (clinicaltrials.gov) - May 23, 2012
P1, N=18, Terminated, Sponsor: Stanford University
Active, not recruiting --> Terminated; Principal Investigator (Dr. Guardino) left Stanford
- Sutent (sunitinib) / Pfizer
Enrollment open, Metastases: Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib (clinicaltrials.gov) - May 22, 2012
P4, N=36, Recruiting, Sponsor: Novartis Pharmaceuticals
Guardino) left Stanford Not yet recruiting --> Recruiting
- Sutent (sunitinib) / Pfizer
Metastases: Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - May 17, 2012
P=N/A, N=20, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- | everolimus / Generic mfg.
Trial completion, Metastases: RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer (clinicaltrials.gov) - May 14, 2012
P2, N=35, Completed, Sponsor: Daniel George
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| everolimus / Generic mfg., cyclosporine / Generic mfg.
New P3 trial, Combination therapy: Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients. (clinicaltrials.gov) - May 13, 2012
P3, N=75, Recruiting, Sponsor: Novartis Pharmaceuticals
- everolimus / Generic mfg.
Metastases: Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma (clinicaltrials.gov) - May 13, 2012
P=N/A, N=97, Recruiting, Sponsor: Centre Francois Baclesse